Biohaven Ltd. appointed John Yetimoglu as a director effective August 6, 2026, to serve in the class expiring at the 2027 Annual Meeting of Shareholders. He was also named to the Nominating and Governance Committee. His compensation includes options with an aggregate grant date fair value of $713,875 vesting over four years and a $57,000 annual retainer. Biohaven Ltd. is a biopharmaceutical company focused on developing treatments for neurological disorders.
